Jelmyto® (UGN-101)

About UroGen Pharma

UroGen Pharma is a commercial-stage biotech focused on transforming the treatment paradigm for urothelial cancers through its proprietary RTGel™ sustained-release hydrogel platform. Its mission is to provide non-surgical, organ-preserving options, validated by the FDA approvals of Jelmyto® for low-grade upper tract urothelial cancer (LG-UTUC) and ZUSDURI™ for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The company's strategy leverages its platform to build a deep pipeline in urologic oncology while executing a targeted commercial launch to establish a new standard of care. Despite a volatile stock price, its ~$830M valuation reflects confidence in its technology and commercial potential.

Therapeutic Areas